Physician profile
Angel Perry
NPI 1750953964
$740.51
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $589 · 2023: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $197.13 | 2022-2023 | Azstarys |
| Lundbeck LLC | $90.87 | 2022-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $88.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $63.15 | 2022-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $50.61 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $30.95 | 2022 | |
| Vanda Pharmaceuticals INC. | $30.00 | 2022 | |
| Ironshore Pharmaceuticals INC. | $23.02 | 2023 | Jornay Pm |
| Alkermes, INC. | $19.91 | 2022 | |
| Axsome Therapeutics, INC. | $19.28 | 2022 | |
| Neos Therapeutics, LP | $15.80 | 2023 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $13.33 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.